Knowledge Library
Fragment Screening and Biophysical Hit Validation at WuXi AppTec’s HitS
Immuno-Oncology Platform to Enable Discovery from Target to Drug
NASH Animal Models and their Clinical Relevance – Quantitative Histopathology of Hepatic Fibrosis
Cancer Immunotherapy and the Application of In Vitro Immunoassays in Drug Development
Novel Peptide Hit Identification and Lead Generating Strategies for Drug Discovery
Enabling Drug Discovery with Diverse Lead Generation Platforms
Aug 2021: Wuxi AppTec immune profiling in drug discovery and CLDN18.2-related tumor models.
Empowering Organic Syntheses with Quantum Mechanics Analyses
Syntheses of specifically functionalized molecules continue to be rate limiting steps (RLS) in drug discovery. Improvement in this RLS means investing only in reactions/synthetic sequences that are more likely to succeed. Structural diversifications, different substitution patterns or unique heterocyclic systems can often adversely impact the crucial step(s) of established synthetic sequences or development of feasible …Read More >
The Synthesis of an Entrepreneur: Merging a Passion for Biochemistry, Synthetic Chemistry, and Bioactive Molecules in Academia
INNOVATION THAT MATTERS By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) Synthetic chemist Joseph Ready believes a huge amount of innovation in the drug industry comes from academia. Academic science is arguably the greatest source of innovation in our ecosystem, yet faces challenges when considering the transition from the lab to early stage …Read More >
